If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [  ]

Note.  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See Rule 13d-7 for other parties to whom copies are to be sent.

CUSIP NO. 253031108

 

* Includes 21,041 shares issuable upon exercise of Warrants.

CUSIP NO. 253031108

 

* Includes 156  shares issuable upon exercise of Warrants.

 

CUSIP NO. 253031108

AMENDMENT NO. 1 TO SCHEDULE 13D

Reference is hereby made to the Statement on Schedule 13D filed with the Securities and Exchange Commission (the "Commission") on behalf of the Reporting Persons with respect to the Common Stock of the Issuer on April 20, 2017 (the "Schedule 13D"). Terms defined in the Schedule 13D are used herein as so defined.

Item 4 is hereby amended and supplemented by adding the information set forth in Item 6 below.

Item 5(a) is hereby amended and restated to read in its entirety as follows:

In addition, Brian K. Halak holds the following options to purchase Common Stock, which are fully-vested or will vest within 60 days of the filing of this statement on Schedule 13D:

Item 5(c) is hereby amended and restated in its entirety to report the transactions described in Item 6 below.

Item 6.

Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Item 6 of the Schedule 13D is hereby amended and supplemented to add the following:

On December 18, 2017, pursuant to a letter agreement dated December 13, 2017 (the "Letter Agreement") among the Issuer and the Investors, all of the outstanding shares of Redeemable Convertible Preferred Stock held by the Reporting Persons were converted into Common Stock (the "Conversion").  The Letter Agreement is Exhibit E to the Schedule 13D, and any description thereof is qualified in its entirety by reference thereto.  In consideration for their agreement to the Conversion and to the waiver and amendment of certain provisions in the Registration Rights Agreement, pursuant to the Letter Agreement the Reporting Persons also received shares of Common Stock representing the additional dividend accruals on the Redeemable Convertible Preferred Stock that the Reporting Persons would have been entitled to receive up to and including March 31, 2018. The total number of shares of Common Stock received by DP VIII and DP VIII A pursuant to the Letter Agreement is 1,716,322 shares and 12,726 shares, respectively. Following such transactions, no shares of Redeemable Convertible Preferred Stock remain outstanding.

The Issuer and the Investors agreed to enter into the First Amendment to Amended and Restated Registration Rights Agreement (the "Registration Rights Agreement Amendment"), pursuant to which the definition of "Registrable Securities" was modified such that the registration rights of the Reporting Persons extend to all shares of Common Stock received pursuant to the Letter Agreement.  The Registration Rights Agreement Amendment is Exhibit F to the Schedule 13D, and any description thereof is qualified in its entirety by reference thereto.

Item 7 of the Schedule 13D is hereby amended and supplemented by adding the following:

 

Exhibit E - Letter Agreement (incorporated by reference to Exhibit 10.1 to the Issuer's Form 8-K filed with the Commission on December 14, 2017)

Exhibit F – Registration Rights Agreement Amendment (incorporated by reference to Exhibit 10.1 to  the Issuer's Form 8-K filed with the Commission on December 18, 2017)

CUSIP NO. 253031108

SIGNATURES

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated:  December 20, 2017